34p 1.0 3.0%
Last Trade - 14/05/21
| Market Cap | £115.3m |
| Enterprise Value | £155.7m |
| Revenue | £n/a |
| Position in Universe | 1005th / 1827 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020E | 2021E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 49.8 | ||||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Advanced Oncotherapy Plc is focused on providing radiotherapy systems for cancer treatment through the use of a proton therapy technology. The Company is engaged in development and then building of the Linac Image Guided Hadron Technology (LIGHT) proton beam cancer therapy device. The Company's segments include Development of Proton Therapy-UK; Development of Proton Therapy-Switzerland; Development of Proton Therapy-USA, and Healthcare-related properties-UK. Its LIGHT system integrates a series of modular linear accelerators. This feature offers hospitals and centers to customize treatment plans based on a range of energies. The Company's Research and development/ADAM S.A. (R&D/ADAM) facility is located on the campus of European Council for Nuclear Research (CERN), Geneva and Switzerland. The Company’s verification and validation site is located in Daresbury, United Kingdom.
| Last Annual | December 31st, 2019 |
| Last Interim | June 30th, 2020 |
| Incorporated | September 15, 2005 |
| Public Since | August 4, 2006 |
| No. of Shareholders: | n/a |
| No. of Employees: | 129 |
| Sector | Healthcare |
| Industry | Healthcare Equipment & Supplies |
| Index | FTSE Aim All Share , |
| Exchange | London Stock Exchange (AIM) |
| Shares in Issue | 349,409,021 |
| Free Float | (0.0%) |
| Eligible for |
✓
ISAs
✓
SIPPs
|
| Address | Third Fl 4 Tenterden Street, LONDON, W1S 1TE, United Kingdom |
| Web | https://www.avoplc.com/ |
| Phone | +44 20 36178728 |
| Contact | () |
| Auditors | RPG Crouch Chapman LLP |
As of 14/05/21, shares in Advanced Oncotherapy are trading at 34p, giving the company a market capitalisation of £115.3m. This share price information is delayed by 15 minutes.
Shares in Advanced Oncotherapy are currently trading at 34p and the price has moved by 17.86% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Advanced Oncotherapy price has moved by -6.79% over the past year.
Of the analysts with advisory recommendations for Advanced Oncotherapy, there are there are currently 0 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Advanced Oncotherapy is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Advanced Oncotherapy is scheduled to issue upcoming financial results on the following dates:
Advanced Oncotherapy does not currently pay a dividend.
Advanced Oncotherapy does not currently pay a dividend.
Advanced Oncotherapy does not currently pay a dividend.
To buy shares in Advanced Oncotherapy you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Advanced Oncotherapy are currently trading at 34p, giving the company a market capitalisation of £115.3m.
Here are the trading details for Advanced Oncotherapy:
Based on an overall assessment of its quality, value and momentum, Advanced Oncotherapy is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Advanced Oncotherapy are currently priced at 34p. At that level they are trading at 0.256% discount to the analyst consensus target price of 34.09.
Analysts covering Advanced Oncotherapy currently have a consensus Earnings Per Share (EPS) forecast of -0.0787 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Advanced Oncotherapy. Over the past six months, the relative strength of its shares against the market has been -1.77%. At the current price of 34p, shares in Advanced Oncotherapy are trading at -7.68% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We were not able to find PE ratio data for Advanced Oncotherapy.
Advanced Oncotherapy's management team is headed by:
Here are the top five shareholders of Advanced Oncotherapy based on the size of their shareholding:
